Is There a Role for Surgery in Patients with Neuroendocrine Tumors of the Esophagus? A Contemporary View from the NCDB
Esophageal neuroendocrine tumors (eNETs) are exceedingly rare, aggressive and have a poor prognosis. Treatment guidelines are ill-defined and mainly based on evidence from case reports and analogous experiences drawn from similar disease sites.
The NCDB was reviewed for histologically confirmed stage I–III, primary eNETs from 2006 to 2014. Patients were grouped into whether or not they underwent primary tumor resection. Univariate, multivariable, and full bipartite propensity score (PS) adjusted Cox regression analyses were used to assess overall and relative survival differences.
A total of 250 patients were identified. Mean age was 65.0 (standard deviation [SD] 11.9) years, and 174 (69.6%) patients were male. Most patients had stage III disease (n = 136, 54.4%), and the most common type of NET was small cell eNET (n = 111, 44.4%). Chemotherapy was used in 186 (74.4%), radiation therapy in 178 (71.2%), and oncological resection was performed in 69 (27.6%) patients. Crude 2-year survival rates were higher in the operated (57.3%) compared with the nonoperated group (35.2%; p < 0.001). The survival benefit held true after multivariable adjustment (hazard ratio [HR] 0.47, 95% confidence interval [CI] 0.32–0.69, p < 0.001). After full bipartite PS adjustment analysis, survival was longer for patients who received a surgical resection compared with those who did not (HR 0.48, 95% CI 0.31–0.75, p = 0.003) with a corresponding 2-year overall survival rate of 63.3% (95% CI 52.0–77.2) versus 38.8% (95% CI 30.9–48.8), respectively.
Multimodal treatment that includes surgery is associated with better overall survival for eNETs. Additional research is needed to more definitively identify patients who benefit from esophagectomy and to establish an appropriate treatment algorithm.
The authors thank the American College of Surgeons and the American Cancer Society for providing patient information through the NCDB used for this investigation. Furthermore, we thank the patients whose information through the NCDB allowed us to perform the investigation for this manuscript.
The author declares that they have no conflict of interest.
- 1.Ilett E, Langer S, Olsen I, Federspiel B, Kjær A. Neuroendocrine carcinomas of the gastroenteropancreatic system: a comprehensive review. Diagnostics. 2015. http://www.mdpi.com/2075-4418/5/2/119/htm. Accessed 28 Aug 2017.
- 3.Deng H, Ni P, Wang Y, Wang W. Neuroendocrine carcinoma of the esophagus: clinical characteristics and prognostic evaluation of 49 cases with surgical resection. J Thorac. 2016. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4886019/. Accessed 28 Aug 2017.
- 4.Lee C, Lim Y, Park S, Jang B. The clinical features and treatment modality of esophageal neuroendocrine tumors: a multicenter study in Korea. BMC. 2014. https://bmccancer.biomedcentral.com/articles/10.1186/1471-2407-14-569. Accessed 28 Aug 2017.
- 8.Caplin ME, Baudin E, Ferolla P, et al. Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids. Ann Oncol. 2015;26(8):1604–20. https://doi.org/10.1093/annonc/mdv041.CrossRefPubMedGoogle Scholar
- 9.Kuo C, Hsieh C, Chan M, Li A. Small cell carcinoma of the esophagus: a report of 16 cases from a single institution and literature review. Ann Thorac. 2011. http://www.sciencedirect.com/science/article/pii/S0003497510021089. Accessed 28 Aug 2017.
- 16.Hu Y, Mcmurry TL, Stukenborg GJ, Kozower BD. Readmission predicts 90-day mortality after esophagectomy: Analysis of Surveillance, Epidemiology, and End Results Registry linked to Medicare outcomes. J Thorac Cardiovasc Surg. 2015;150:1254–60. https://doi.org/10.1016/j.jtcvs.2015.08.071.CrossRefPubMedPubMedCentralGoogle Scholar
- 20.Ho DE, Imai K, King G, Stuart EA. MatchIt: Nonparametric Preprocessing for Parametric Causal Inference. Vol. 42; 2011. http://www.jstatsoft.org/. Accessed 26 Oct 2018.
- 23.Series PH-ERR, 1988 undefined. Causal inference, path analysis and recursive structural equations models. Wiley Online Libr. http://onlinelibrary.wiley.com/doi/10.1002/j.2330-8516.1988.tb00270.x/full. Accessed 18 Feb 2018.
- 26.Funakoshi S, Hashiguchi A, Teramoto K, et al. Second-line chemotherapy for refractory small cell neuroendocrine carcinoma of the esophagus that relapsed after complete remission with irinotecan plus cisplatin therapy: case report and review of the literature. Oncol Lett. 2013;5(1):117–22. https://doi.org/10.3892/ol.2012.1008.CrossRefPubMedGoogle Scholar
- 28.Kuo CH, Hsieh CC, Chan ML, et al. Small cell carcinoma of the esophagus: a report of 16 cases from a single institution and literature review. Ann Thorac Surg. 2011. http://dx.doi.org/10.1016/j.athoracsur.2010.09.030.CrossRefPubMedGoogle Scholar
- 31.Chen S, Yang J, Yang W, Weng H. Treatment and prognosis of limited disease primary small cell carcinoma of esophagus. Dis. 2011. https://academic.oup.com/dote/article-abstract/24/2/114/2328443. Accessed 21 Sept 2017.
- 33.Dhungel B, Diggs BS, Hunter JG, Sheppard BC, Vetto JT, Dolan JP. Patient and peri-operative predictors of morbidity and mortality after esophagectomy: American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP), 2005-2008. J Gastrointest Surg. 2010;14(10):1492–501. https://doi.org/10.1007/s11605-010-1328-2.CrossRefPubMedGoogle Scholar